MDT · 10-Q · 2026Q3 · Full report
Capital Return Program
Medtronic plc · 2026-09-03 · Importance 40 · Surprise 42 · In source text
Medtronic’s March 2024 board authorization permits up to $5.0 billion of ordinary-share repurchases without a specified expiration date. During the three months ended July 31, 2026, Medtronic repurchased 3 million shares at an average price of $81.56. Approximately $1.0 billion remained available under the authorization at July 31, 2026. Net cash used in financing activities also reflected a $219 million year-over-year increase in share repurchases.
Key facts
- In March 2024, Medtronic's Board authorized the repurchase of $5.0 billion of the Company's ordinary shares with no specific time period associated with the authorization. source
- At July 31, 2026, Medtronic had approximately $1.0 billion remaining under the share repurchase program authorized by the Board of Directors. source
- During the three months ended July 31, 2026, Medtronic repurchased 3 million shares under the repurchase program at an average price of $81.56. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -0.9% | At July 31, 2026, Medtronic had approximately $1.0 billion remaining under the share repurchase program authorized by the Board of… |